Case report: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 8, 1999, Pages 804-806

  Liaw, Yun Fan ^a   Chien, Rong Nan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis B; Corticosteroid priming; Hepatitis B virus; Immunomodulation; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; CORTICOSTEROID THERAPY; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNOMODULATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEROCONVERSION;

EID: 0032836849     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01960.x     Document Type: Article

References (14)

1. 1 Nicoll A, Locarnini S. Present and future directions in the treatment of chronic hepatitis B infection. J. Gastroenterol. Hepatol. 1997; 12: 843-54.
2. 2 Mason WS, Cullen J, Moraleda G et al. Lamivudine therapy of WHV-infected woodchucks. Virology 1998; 245: 18-32.
3. 3 Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657-61.
4. 4 Liaw YF, Chien RN, Sheen IS, Lai MY, Chen DS. A randomized, controlled, dose-ranging study of lamivudine in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 1995; 10: S68.
5. 5 Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B. A six-month randomized dose-ranging study. Gastroenterology 1997; 113: 1258-63.
6. 6 Lai CL, Chien RN, Leung NWY et al. A one year trial of lamividine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61-8.
7. 7 Liaw YF, Lai CL, Leung NWY et al. Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multi-center study in Asia. Gastroenterology 1998; 114: A1289.
8. 8 Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 1998; 29: 151-68.
9. 9 Schiff E, Cianciara J, Kowdley K et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. Hepatology 1998; 28: 163A.
10. 10 Chien RN, Liaw YF, Atkins M. Pretherapy alanine amino-transferase level as a determinant for HBeAg seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; (in press).
11. 11 Liaw YF. Hepatitis viruses under immunosuppressive agents. J. Gastroenterol. Hepatol. 1998; 13: 14-20.
12. 12 Liaw YF. Current trends in therapy for chronic viral hepatitis. J. Gastroenterol. Hepatol. 1997; 12: S346-53.
13. 13 Kao JH, Wood M, Chen CJ, Lai MY, Chen DS. Comparison of two methods for quantitation of hepatitis B viral DNA. J. Gastroenterol. Hepatol. 1999; 14: 423-6.
14. 14 Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: Incidence and risk factors. J. Gastroenterol. Hepatol. 1996; 11: 143-7.